IMC Chicago’s Intellia Therapeutics NTLA Stock Holding History

IMC Chicago’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,771	Closed	-$179K	–	6641
2026 Q1	$164K	Sell	12,771 -18,132	-59%	-$231K	﹤0.01%	5122
2025 Q4	$278K	Buy	+30,903	New	+$425K	﹤0.01%	3849

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IMC Chicago's NTLA Position: Q2 2026 in Review

IMC Chicago sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 12,771 shares — an estimated $179K sold.

IMC Chicago first reported a position in NTLA in Q4 2025 and held it in 2 quarters. The position peaked at $278K in Q4 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

IMC Chicago reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 12,771 Intellia Therapeutics shares in Q2 2026, an estimated $179K.
IMC Chicago first reported a position in Intellia Therapeutics in Q4 2025 and held it in 2 quarters.
IMC Chicago's Intellia Therapeutics position peaked at $278K in Q4 2025.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.